Christopher Striebich is a Rheumatology/Immunology physician affiliated with University of Colorado Anschutz. OpenAlex indexes 41 publications with 1,204 citations (h-index 18); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 4 Apr 2013.
Clinical trials
- Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- IDORSIA PHARMACEUTICALS US INCProgram year20243 payments
- AstraZeneca UK LimitedProgram year202313 payments
- Biogen, Inc.Program year202312 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
60.1%TNF inhibitor27.6%Humira(Cf) Pen38%Enbrel Sureclick31%Humira(Cf)31%Part D<11 patientsFolate Analog Metabolic Inhibitor16.5%Methotrexate100%Part D≥27 patients+ 4 more classes in this area
Metabolism & gastrointestinal
21.3%Corticosteroid14.2%Prednisone100%Part D≥19 patientsAntidiarrheal microorganisms4.2%Folic Acid100%Part D<11 patients+ 1 more class in this area
Antiparasitic
12.3%Antimalarial12.3%Hydroxychloroquine Sulfate100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2008 per NIH RePORTER. The latest:
- TREATMENT OF PSORIATIC ARTHRITIS WITH HOKT3Y1 (ALA-ALA)
University of Colorado Denver
FY2008$1,028M01RR000051 - TREATMENT OF PSORIATIC ARTHRITIS WITH HOKT3Y1 (ALA-ALA)
University of Colorado Denver
FY2007$8,752M01RR000051 - STUDY OF AN ANTIBODY FOR ANTI-B CELL THRPY IN TRTMNT OF SYSTMC LUPUS ERYTHMATOSU
University of Colorado Denver
FY2005$2,573M01RR000051
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
Arthritis & Rheumatology
2025 - Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation
Science Translational Medicine
2025 - A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
Arthritis & Rheumatology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
David Badesch, MD
University of Colorado Anschutz
Sarit Polsky, MD, MPH
University of Colorado Anschutz
Maria Nagel, MD
University of Colorado Anschutz
Tyler Buckner, MD
University of Colorado Anschutz
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”